DK3463435T3 - Alpha-synuklein-antistoffer og anvendelser deraf - Google Patents

Alpha-synuklein-antistoffer og anvendelser deraf Download PDF

Info

Publication number: DK3463435T3
Authority: DK; Denmark
Prior art keywords: alpha; synuclein antibodies; synuclein; antibodies
Prior art date: 2016-06-02

Application number

DK17728525.1T

Other languages

English (en)

Inventor

Michael Perkinton

Darren Schofield

Lorraine Irving

George Thom

Original Assignee

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-02

Filing date

2017-06-01

Publication date

2021-11-22

2017-06-01 Application filed by Medimmune Ltd filed Critical Medimmune Ltd

2021-11-22 Application granted granted Critical

2021-11-22 Publication of DK3463435T3 publication Critical patent/DK3463435T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)

DK17728525.1T 2016-06-02 2017-06-01 Alpha-synuklein-antistoffer og anvendelser deraf DK3463435T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662344746P	2016-06-02	2016-06-02
PCT/EP2017/063406 WO2017207739A1 (en)	2016-06-02	2017-06-01	Antibodies to alpha-synuclein and uses thereof

Publications (1)

Publication Number	Publication Date
DK3463435T3 true DK3463435T3 (da)	2021-11-22

Family

ID=59021492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17728525.1T DK3463435T3 (da)	2016-06-02	2017-06-01	Alpha-synuklein-antistoffer og anvendelser deraf

Country Status (37)

Country	Link
US (5)	US10160800B2 (da)
EP (2)	EP4000632A1 (da)
JP (3)	JP7078552B2 (da)
KR (1)	KR102499438B1 (da)
CN (2)	CN109475616B (da)
AR (1)	AR108663A1 (da)
AU (2)	AU2017272804B2 (da)
BR (1)	BR112018074978A2 (da)
CA (1)	CA3025987A1 (da)
CL (1)	CL2018003438A1 (da)
CO (1)	CO2018014010A2 (da)
CY (1)	CY1124896T1 (da)
DK (1)	DK3463435T3 (da)
EA (2)	EA202191380A1 (da)
EC (1)	ECSP18096095A (da)
ES (1)	ES2903402T3 (da)
GE (2)	GEAP202114964A (da)
HR (1)	HRP20211935T1 (da)
HU (1)	HUE057214T2 (da)
IL (1)	IL263243A (da)
LT (1)	LT3463435T (da)
MA (1)	MA45125B1 (da)
MD (1)	MD3463435T2 (da)
MX (1)	MX393740B (da)
MY (1)	MY188183A (da)
PE (2)	PE20250392A1 (da)
PH (1)	PH12018502538A1 (da)
PL (1)	PL3463435T3 (da)
PT (1)	PT3463435T (da)
RS (1)	RS62682B1 (da)
SG (1)	SG11201810420YA (da)
SI (1)	SI3463435T1 (da)
SM (1)	SMT202200008T1 (da)
TW (2)	TWI765890B (da)
UA (1)	UA124733C2 (da)
WO (1)	WO2017207739A1 (da)
ZA (1)	ZA201808582B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201512203D0 (en)	2015-07-13	2015-08-19	Lundbeck & Co As H	Agents,uses and methods
AR110074A1 (es) *	2016-11-15	2019-02-20	H Lundbeck As	Agentes, usos y métodos para el tratamiento de la sinucleinopatía
ES3008133T3 (en)	2016-12-16	2025-03-21	H Lundbeck As	Agents, uses and methods
US10364286B2 (en)	2016-12-22	2019-07-30	H. Lundbeck A/S	Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EA201991720A1 (ru)	2017-02-17	2020-01-20	Бристол-Маерс Сквибб Компани	Антитела к альфа-синуклеину и их применения
GB201720970D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Antibodies
GB201720975D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Anti-alpha synuclein antibodies
EA202190807A1 (ru) *	2018-10-19	2021-08-06	Янссен Вэксинс Энд Превеншн Б.В.	Антитела к синуклеину
TWI734279B (zh) *	2018-12-14	2021-07-21	美商美國禮來大藥廠	抗α-突觸核蛋白抗體及其用途
MX2021012608A (es)	2019-04-18	2021-11-12	Ac Immune Sa	Nuevas moleculas para terapia y diagnostico.
CN110172098B (zh) *	2019-05-27	2023-03-10	长春工业大学	抗α-突触核蛋白的单克隆抗体及其应用
WO2021055881A1 (en)	2019-09-20	2021-03-25	Denali Therapeutics Inc.	Anti-alpha-synuclein antibodies and methods of use thereof
KR102239512B1 (ko) *	2020-09-10	2021-04-12	서울대학교산학협력단	다중기능성 마이크로캡슐 조성물 및 그 제조방법
EP4229082A1 (en)	2020-10-16	2023-08-23	AC Immune SA	Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112920274A (zh) *	2021-03-17	2021-06-08	江苏贝格尔生物医药有限公司	一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CN113912716B (zh) *	2021-12-15	2022-03-01	北京凯祥弘康生物科技有限公司	针对α-突触核蛋白抗原的抗体及其应用
EP4642798A1 (en)	2022-12-29	2025-11-05	Astrazeneca AB	Compositions and methods for treating alpha-synucleinopathies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU778392B2 (en)	2000-03-03	2004-12-02	Cambridge Antibody Technology Limited	Human antibodies against eotaxin and their use
EP1328626B1 (en)	2000-05-26	2013-04-17	National Research Council Of Canada	Single-domain brain-targeting antibody fragments derived from llama antibodies
EP2082749A3 (en)	2000-07-07	2010-06-30	Bioarctic Neuroscience AB	Prevention and treatment of Alzheimer's disease
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US20080014194A1 (en)	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en)	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
WO2005013889A2 (en)	2003-05-19	2005-02-17	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in lewy body disease
WO2005047860A2 (en)	2003-11-08	2005-05-26	Elan Pharmaceuticals, Inc.	Antibodies to alpha-synuclein
EA013752B1 (ru)	2004-08-09	2010-06-30	Элан Фармасьютикалз, Инк.	Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
EP1943341A4 (en)	2005-09-27	2010-07-07	Ca Nat Research Council	BLOOD-BRAIN-SPEED-EPITOPES AND USES THEREOF
US8147833B2 (en)	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2583978T3 (pl)	2007-02-23	2016-07-29	Prothena Biosciences Ltd Co	Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
JP4934074B2 (ja)	2007-03-07	2012-05-16	株式会社アルファ	スイッチ固定構造
PT2282758T (pt)	2008-04-29	2019-02-12	Bioarctic Ab	Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
AU2009328505B2 (en)	2008-12-19	2014-11-27	Panima Pharmaceuticals Ag	Human anti-alpha-synuclein autoantibodies
JP4654348B1 (ja)	2010-02-23	2011-03-16	多摩川精機株式会社	検出装置用巻線の正弦波巻線方法
HUE038313T2 (hu)	2010-02-26	2018-10-29	Bioarctic Neuroscience Ab	Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban
EA030777B9 (ru)	2011-06-23	2019-02-28	Байоджен Интернэшнл Нейросайенз Гмбх	Анти-альфа-синуклеинсвязывающие молекулы
DK3378535T5 (da)	2011-10-28	2024-09-30	Prothena Biosciences Ltd	Humanserede antistoffer, der genkender alpha-synuklein
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) *	2013-02-28	2017-01-03	United Arab Emirates University	Alpha-synuclein antibodies and uses thereof
RU2718990C1 (ru) *	2013-11-21	2020-04-15	Ф. Хоффманн-Ля Рош Аг	Антитела к альфа-синуклеину и способы применения
SG11201703332SA (en)	2014-11-10	2017-05-30	Medimmune Ltd	Binding molecules specific for cd73 and uses thereof

2017
- 2017-06-01 PE PE2023002924A patent/PE20250392A1/es unknown
- 2017-06-01 MY MYPI2018002168A patent/MY188183A/en unknown
- 2017-06-01 EP EP21202106.7A patent/EP4000632A1/en active Pending
- 2017-06-01 DK DK17728525.1T patent/DK3463435T3/da active
- 2017-06-01 BR BR112018074978-8A patent/BR112018074978A2/pt active Search and Examination
- 2017-06-01 LT LTEPPCT/EP2017/063406T patent/LT3463435T/lt unknown
- 2017-06-01 EA EA202191380A patent/EA202191380A1/ru unknown
- 2017-06-01 PT PT177285251T patent/PT3463435T/pt unknown
- 2017-06-01 CA CA3025987A patent/CA3025987A1/en active Pending
- 2017-06-01 HU HUE17728525A patent/HUE057214T2/hu unknown
- 2017-06-01 EA EA201892548A patent/EA038358B1/ru unknown
- 2017-06-01 SG SG11201810420YA patent/SG11201810420YA/en unknown
- 2017-06-01 MA MA45125A patent/MA45125B1/fr unknown
- 2017-06-01 WO PCT/EP2017/063406 patent/WO2017207739A1/en not_active Ceased
- 2017-06-01 US US15/611,416 patent/US10160800B2/en active Active
- 2017-06-01 SM SM20220008T patent/SMT202200008T1/it unknown
- 2017-06-01 MD MDE20190406T patent/MD3463435T2/ro unknown
- 2017-06-01 PL PL17728525T patent/PL3463435T3/pl unknown
- 2017-06-01 TW TW106118078A patent/TWI765890B/zh active
- 2017-06-01 GE GEAP202114964A patent/GEAP202114964A/en unknown
- 2017-06-01 RS RS20211502A patent/RS62682B1/sr unknown
- 2017-06-01 JP JP2018563050A patent/JP7078552B2/ja active Active
- 2017-06-01 ES ES17728525T patent/ES2903402T3/es active Active
- 2017-06-01 SI SI201731025T patent/SI3463435T1/sl unknown
- 2017-06-01 KR KR1020187037675A patent/KR102499438B1/ko active Active
- 2017-06-01 CN CN201780045951.2A patent/CN109475616B/zh active Active
- 2017-06-01 MX MX2018014456A patent/MX393740B/es unknown
- 2017-06-01 UA UAA201811679A patent/UA124733C2/uk unknown
- 2017-06-01 TW TW111117603A patent/TW202309093A/zh unknown
- 2017-06-01 HR HRP20211935TT patent/HRP20211935T1/hr unknown
- 2017-06-01 CN CN202211223767.1A patent/CN116120445A/zh active Pending
- 2017-06-01 AR ARP170101504A patent/AR108663A1/es unknown
- 2017-06-01 GE GEAP201714964A patent/GEP20217253B/en unknown
- 2017-06-01 AU AU2017272804A patent/AU2017272804B2/en active Active
- 2017-06-01 PE PE2018003155A patent/PE20190440A1/es unknown
- 2017-06-01 EP EP17728525.1A patent/EP3463435B1/en active Active
2018
- 2018-10-25 US US16/170,468 patent/US10889639B2/en active Active
- 2018-11-22 IL IL263243A patent/IL263243A/en unknown
- 2018-11-29 PH PH12018502538A patent/PH12018502538A1/en unknown
- 2018-11-30 CL CL2018003438A patent/CL2018003438A1/es unknown
- 2018-12-19 ZA ZA2018/08582A patent/ZA201808582B/en unknown
- 2018-12-21 CO CONC2018/0014010A patent/CO2018014010A2/es unknown
- 2018-12-28 EC ECSENADI201896095A patent/ECSP18096095A/es unknown
2020
- 2020-12-03 US US17/111,159 patent/US11560424B2/en active Active
2022
- 2022-01-05 CY CY20221100010T patent/CY1124896T1/el unknown
- 2022-05-19 JP JP2022082099A patent/JP2022110117A/ja active Pending
2023
- 2023-01-20 US US18/099,671 patent/US20230331830A1/en active Pending
2024
- 2024-01-31 AU AU2024200601A patent/AU2024200601A1/en active Pending
- 2024-06-27 JP JP2024103562A patent/JP2024123247A/ja active Pending
2025
- 2025-01-16 US US19/025,554 patent/US20250263477A1/en active Pending

Also Published As

Publication number	Publication date
JP7078552B2 (ja)	2022-05-31
TWI765890B (zh)	2022-06-01
AU2024200601A1 (en)	2024-04-18
JP2019527194A (ja)	2019-09-26
EA201892548A1 (ru)	2019-06-28
AU2017272804A1 (en)	2018-12-13
KR20190013923A (ko)	2019-02-11
CY1124896T1 (el)	2023-01-05
LT3463435T (lt)	2021-12-27
EP3463435A1 (en)	2019-04-10
AR108663A1 (es)	2018-09-12
PT3463435T (pt)	2021-11-22
GEP20217253B (en)	2021-05-13
ZA201808582B (en)	2021-08-25
ECSP18096095A (es)	2019-01-31
SMT202200008T1 (it)	2022-03-21
JP2024123247A (ja)	2024-09-10
MX2018014456A (es)	2019-08-12
MA45125A (fr)	2021-06-02
NZ748616A (en)	2025-08-29
TW202309093A (zh)	2023-03-01
WO2017207739A1 (en)	2017-12-07
BR112018074978A2 (pt)	2019-03-12
HUE057214T2 (hu)	2022-04-28
US20230331830A1 (en)	2023-10-19
US20190276522A1 (en)	2019-09-12
UA124733C2 (uk)	2021-11-10
PE20250392A1 (es)	2025-02-11
PH12018502538A1 (en)	2019-04-08
RS62682B1 (sr)	2021-12-31
EP4000632A1 (en)	2022-05-25
GEAP202114964A (en)	2021-01-25
CN109475616B (zh)	2022-10-18
HRP20211935T1 (hr)	2022-03-18
MX393740B (es)	2025-03-24
US10889639B2 (en)	2021-01-12
EA038358B1 (ru)	2021-08-13
SG11201810420YA (en)	2018-12-28
US10160800B2 (en)	2018-12-25
KR102499438B1 (ko)	2023-02-14
CL2018003438A1 (es)	2019-03-22
CO2018014010A2 (es)	2019-01-18
TW201802119A (zh)	2018-01-16
ES2903402T3 (es)	2022-04-01
CA3025987A1 (en)	2017-12-07
CN116120445A (zh)	2023-05-16
EP3463435B1 (en)	2021-10-13
CN109475616A (zh)	2019-03-15
EA202191380A1 (ru)	2021-08-26
US20210179698A1 (en)	2021-06-17
US20250263477A1 (en)	2025-08-21
PL3463435T3 (pl)	2022-02-14
US11560424B2 (en)	2023-01-24
MY188183A (en)	2021-11-24
AU2017272804B2 (en)	2023-11-23
PE20190440A1 (es)	2019-03-27
IL263243A (en)	2018-12-31
MD3463435T2 (ro)	2022-03-31
JP2022110117A (ja)	2022-07-28
US20180002411A1 (en)	2018-01-04
SI3463435T1 (sl)	2022-02-28
MA45125B1 (fr)	2021-11-30

Publication	Publication Date	Title
DK3625263T3 (da)	2025-06-30	Anti-galectin- 9-antistoffer og anvendelser deraf
DK3383916T3 (da)	2022-03-28	Anti-CD73-antistoffer og anvendelser deraf
DK3463435T3 (da)	2021-11-22	Alpha-synuklein-antistoffer og anvendelser deraf
IL262095A (en)	2018-11-29	Anti-pacap antibodies and uses thereof
DK3458479T3 (da)	2021-02-08	Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
IL262437A (en)	2018-12-31	Bispecific binding proteins and uses thereof
DK3468990T3 (da)	2024-06-24	Anti-C5-antistoffer og anvendelser deraf
DK3443009T3 (da)	2021-12-13	Anti-tim-3-antistoffer og sammensætninger
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3596125T3 (da)	2025-12-22	Anti-PAR2-antistoffer og anvendelser deraf
DK3532499T3 (da)	2021-06-28	ANTI-IL-33-antistoffer og anvendelser deraf
DK3504242T3 (da)	2020-08-17	Anti-ox40-antistoffer og anvendelse deraf
DK3515487T5 (da)	2024-09-02	Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater
DK3347379T5 (da)	2020-06-15	Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
DK3402821T3 (da)	2023-11-06	Psma-bindende antistof og anvendelser deraf
DK3229838T3 (da)	2020-10-19	Anti-C10orf54-antistoffer og anvendelser deraf
DK3307274T3 (da)	2020-11-09	Anti-cd123-antistoffer og konjugater deraf
DK3350220T3 (da)	2021-07-12	Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3365368T3 (da)	2023-06-26	Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3126388T3 (da)	2019-07-29	Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3258951T3 (da)	2020-04-06	Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3274370T3 (da)	2020-02-17	Anti-ceacam6-antistoffer og anvendelser deraf
DK3316909T5 (da)	2024-10-07	Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
IL263273A (en)	2018-12-31	Anti-gitr antibodies and uses thereof
DK3561057T3 (da)	2025-10-27	Anti-cd3-antistof og molekyle indeholdende nævnte antistof